Page 23 - MBCA_FULL REPORT_FINAL_FOR_WEB

advanced breast cancer includes both metastatic breast cancer and locally advanced breast cancer
(stage III) and locally recurrent breast cancer
Akt a serine/threonine-specific protein kinase
BRCA mutation mutation in the tumor-suppressor gene BRCA1 or BRCA2,
associated with hereditary breast cancer
CSO Common Scientific Outline (www.icrpartnership.org/CSO.cfm)
de novo MBC breast cancer that is metastatic at the time of first diagnosis

ER– estrogen receptor negative/hormone insensitive breast cancer
ER+ estrogen receptor positive/hormone sensitive breast cancer
ErbB epidermal growth factor receptor (protein family)
gHRAsp Grants in the Health Research Alliance Shared Portfolio (www.ghrasp.org),
HCPs HCPs
HER2 human epidermal growth factor receptor 2
hormone-sensitive MBC MBC where tumor growth is promoted by estrogen and/or progesterone
HRA Health Research Alliance
ICRP International Cancer Research Partnership

incidence Rate of occurrence of new cases in the population (measure risk of
developing a disease)
IOM Institute of Medicine
KOL key opinion leader
MBC metastatic breast cancer
MBC Alliance Metastatic Breast Cancer Alliance (also called the Alliance)

mTOR mechanistic target of rapamycin (serine/threonine protein kinase)
NCI National Cancer Institute
PDQ Physician Data Query
PI3K phosphatidylinositide 3-kinase
prevalence proportion of cases in the population (measures how widespread the disease is)
RECIST Response Evaluation Criteria in Solid Tumors
SEER Surveillance, Epidemiology, and End Results program of the
National Cancer Institute (NCI)
stage IV breast cancer another term for metastatic breast cancer
TBCRC Translational Breast Cancer Research Consortium
TN MBC triple-negative (hormone insensitive and HER2-negative) metastatic breast cancer
TNBC triple-negative (hormone insensitive) breast cancer
US United States

23